Simvastatin Inhibits Renal Cancer Cell Growth and Metastasis via AKT/mTOR, ERK and JAK2/STAT3 Pathway

• DOI: 10.1371/journal.pone.0062823
• Publication Date: 2013-05-17T17:13:43Z
• Authors: Zhiqing Fang; Yueqing Tang; Juanjuan Fang; Zunlin Zhou; Zhaoquan Xing; Zhaoxin Guo; Xiaoyu Guo; Weichang Wang; Wei Jiao; Zhonghua Xu; Zhaoxu Liu
• Keywords: Viability assay

Renal cell carcinoma (RCC) is the most lethal type of genitourinary cancer due to its occult onset and resistance chemotherapy radiation. Recently, accumulating evidence has suggested stains, inhibitors 3-hydroxy-3-methyl glutaryl coenzyme A (HMG-CoA) reductase, were associated with risk reduction cancer. In present study, we aimed investigate potential effects simvastatin on RCC cells underlying mechanisms by which exerted actions. With viability, colony formation, flow cytometric apoptosis assays, found that potently suppressed growth A498 786-O in a time- dose- dependent manner. Consistently, xenograft model performed nude mice exhibited reduced tumor treatment. addition, inhibitory migration invasion also observed vitro. Mechanically, presented could suppress proliferation motility via inhibiting phosphorylation AKT, mTOR, ERK Further investigation mechanism revealed exert anti-tumor suppressing IL-6-induced JAK2 STAT3. conclusion, these findings simvastatin-induced anti-metastasis activity accompanied inhibition AKT/mTOR, ERK, JAK2/STAT3 pathways, imply may be therapeutic agent for treatment patients.